Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · December 28, 2021

Oral Nalbuphine May Improve Itch and Lesions in Patients With Prurigo Nodularis

Journal of the European Academy of Dermatology and Venereology: JEADV

 

Additional Info

Journal of the European Academy of Dermatology and Venereology: JEADV
Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase
J Eur Acad Dermatol Venereol 2021 Nov 15;[EPub Ahead of Print], E Weisshaar, JC Szepietowski, JD Bernhard, H Hait, FJ Legat, L Nattkemper, A Reich, B Sadoghi, TR Sciascia, C Zeidler, G Yosipovitch, S Ständer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading